TABLE 1.
Decreases in bacterial counts from TCF at day 8 and day 11 and bacterial counts recovered from CVs at day 11
| Therapy regimen or groupa | Bacterial count, mean log CFU/ml ± SD (no. of samples)b |
||
|---|---|---|---|
| TCF |
CVs | ||
| Day 8 | Day 11 | ||
| Monotherapies | |||
| RIF | −2.59 ± 0.91 (20)** | −2.75 ± 1.35 (19)* | 1.69 ± 1.26 (19)* |
| DAP100 | −3.14 ± 0.74 (15)** | −3.59 ± 0.49 (15)*** | 1.88 ± 0.92 (15) |
| DAP45 | −2.54 ± 1.21 (25)* | −2.71 ± 1.56 (22)* | 2.11 ± 1.41 (22) |
| Combination therapies | |||
| LNZ+RIF | −2.38 ± 1.17 (20) | −3.23 ± 1.45 (19) | 1.76 ± 1.27 (19) |
| VAN+RIF | −2.62 ± 1.19 (20) | −3.73 ± 1.48 (20) | 1.23 ± 0.52 (20) |
| DAP100+RIF | −4.57 ± 0.69 (17)†† | −4.58 ± 0.68 (17)†† | 0.95 ± 0.13 (17)†† |
| DAP45+RIF | −4.21 ± 0.99 (18)†† | −4.38 ± 0.92 (18)† | 0.91 ± 0.32 (18)†† |
| Control | 0.66 ± 1.24 (19) | 1.14 ± 1.16 (11) | 5.58 ± 0.97 (11) |
a
RIF, rifampin; DAP100, daptomycin at 100 mg/kg/day; DAP45, daptomycin at 45 mg/kg/day; LNZ, linezolid; VAN, vancomycin.
b
Data for vancomycin and linezolid alone are not shown. All therapeutic groups performed significantly better than controls (P < 0.05). Among monotherapies, *, P < 0.05 versus linezolid; **, P < 0.05 versus linezolid and vancomycin; and ***, P < 0.05 versus linezolid, vancomycin, rifampin, and daptomycin at 45 mg/kg/day. Among combination therapies, †, P < 0.05 versus linezolid-rifampin, and ††, P < 0.05 versus linezolid-rifampin and vancomycin-rifampin.